Ionis Pharmaceuticals (IONS) EBIT (2009 - 2026)

Ionis Pharmaceuticals' EBIT history runs 18 years deep, the most recent figure standing at -$102.3 million for Q2 2026.

• In Q2 2026, EBIT fell 173.16% year-over-year to -$102.3 million; the TTM figure through Jun 2026 stood at -$594.4 million (down 123.01% YoY), while the FY2025 annual figure was -$381.7 million, up 19.66% from the prior year.
• EBIT for Q2 2026 stood at -$102.3 million, up from -$117.4 million in the prior quarter.
• The five-year high for EBIT was $139.8 million in Q2 2025, with the low at -$214.5 million in Q4 2025.
• The 5-year median for EBIT is -$112.5 million (2023), against an average of -$102.2 million.
• The sharpest annual moves came in 2024 and 2025: EBIT tumbled 1710.21% in 2024, then surged 311.55% in 2025.
• Ionis Pharmaceuticals' EBIT stood at -$208.0 million in 2022, then soared by 97.06% to -$6.1 million in 2023, then sank by 1710.21% to -$110.8 million in 2024, then sank by 93.52% to -$214.5 million in 2025, then soared by 52.3% to -$102.3 million in 2026.
• Business Quant data shows IONS's EBIT at -$102.3 million in Q2 2026, -$117.4 million in Q1 2026, and -$214.5 million in Q4 2025.